Testosterone replacement biotech Clarus Therapeutics withdraws $86 million IPO
Clarus Therapeutics, a biotech awaiting FDA approval for an oral testosterone replacement therapy, withdrew its plans for a planned $86 million initial public offering on Wednesday. The Northbrook, IL-based company was founded in 2003 and previously withdrew an IPO filing in July 2011. Citi and Credit Suisse were set to be the joint bookrunners on the deal.
The article Testosterone replacement biotech Clarus Therapeutics withdraws $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.